Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” fourth quarter 2024 ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Polen Global Growth Strategy stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its Q4 2024 investor letter: “The largest relative detractors in the quarter were Novo Nordisk A/S ...

Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Ladies and gentlemen, thank you for standing by. My name is Jale, and I will be your conference operator today. At this time, I would like to ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...

Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.

HIGHLIGHTS •Aircore drilling to test priority targets expected to commence in late-March, weather dependent, at the Balla ...